Sarepta exceeds revenue forecasts, maintains 2025 guidance By Investing.com

CAMBRIDGE, Mass. Sarepta Therapeutics, Inc. (NASDAQ: ) the $11.95 billion market cap biotechnology company specializing in the genetic medicine of rare diseases, today reported preliminary financial results, showing significant growth in fourth quarter and full year 2024 revenue. InvestingPro: According to the data, the company has maintained impressive revenue growth of 48.45% over the past twelve months, reflecting its strong market position.The company reported total net product revenue of $638.2 million for the fourth quarter and $1.79 billion for the full year. for, beating its full-year guidance by more than $100 million.

The company’s gene therapy for Duchenne muscular dystrophy generated $384.2 million in net revenue in the fourth quarter, beating expectations by more than $60 million RNA-based PMO products brought in $254.0 million in the fourth quarter and $967.2 million for the full year.

Sarepta’s cash reserves, including cash equivalents, restricted cash and investments, were approximately $1.5 billion as of December 31, 2024. The company’s strong liquidity position is evidenced by a healthy current ratio of 3.84, where liquid assets are significantly exceed current liabilities.The company also reiterated its full-year 2025 revenue guidance, projecting net product revenue of $2.9 to $3.1 billion. InvestingPro: analysis shows that the company maintains a good overall financial health score, with particularly strong growth and profitability metrics.

Sarepta President and CEO Doug Ingram highlighted the company’s strong performance, noting a 75% year-over-year increase in total net product revenue for the fourth quarter. Ingram highlighted the success of the ELEVIDYS launch and the continued growth of the PMO franchise.

These preliminary financial results are unaudited and subject to adjustment. Sarepta will report its final and full financial results by the end of February 2025. Analysts are maintaining growth forecasts for the stock with significant upside potential. The company has not yet completed its financial closing procedures for the year and actual results may differ from these preliminary figures.For a deeper understanding of Sarepta’s financial health and growth prospects, incl 12 additional ProTips and comprehensive evaluation metrics, check out the full research report available on the website. InvestingPro:.

This financial update is based on a press release from Sarepta Therapeutics. The company will provide more details after the final numbers are released.

In other recent news, Sarepta Therapeutics has been the focus of several analysts. was also noted for its revenue growth potential and strong financial health by InvestingPro.The company’s recent strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: It plans to add 13 RNAi programs to its pipeline by early 2025. The move has drawn interest from various financial firms, including Piper Sandler, Needham, Morgan Stanley (NYSE:), and Mizuho (NYSE:) maintained positive ratings on Sarepta shares.Despite the bullish outlook, HC Wainwright lowered its price target on Sarepta to a “sell” rating.These are the latest developments for Sarepta Therapeutics.

Regeneron ( NASDAQ: ) Pharmaceuticals also received a spotlight from RBC Capital Markets, which gave the company an “Outperform” rating.Despite the potential competition, the company maintains that Regeneron’s fundamentals remain strong with new treatments with a promising outlook for the launch.The company’s stock has also been given an “Outperform” rating by BMO Capital Markets, indicating confidence in the company’s position and growth potential.These are the latest developments for Regeneron Pharmaceuticals are

Amgen Inc (NASDAQ: ), Legend Biotech and Axsome Therapeutics (NASDAQ: ) also received an Outperform rating from RBC Capital.The firm sees potential for these companies in the coming year based on new product launches, clinical trial readings and on sales growth expectations These are the latest developments for these companies.

This article is powered by AI and reviewed by an editor. See our T&C for more information.